Speedy approval for Amgen's Blincyto

FDA granted accelerated approval to Blincyto blinatumomab from Amgen Inc. (NASDAQ:AMGN) to treat Philadelphia chromosome-negative precursor B cell acute lymphoblastic leukemia (ALL),

Read the full 223 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE